Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine ...

The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Groundbreaking single-dose vaccine found effective in preventing HIV - Strategy may lead to new vaccines that only need to be ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...